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Abstract
This paper presents the findings of a study to assess the effectiveness and sustainability of a GAVI (Global Alliance of
Vaccines and Immunization) sponsored, time-limited Injection Safety (INS) support. The support came in two forms: 1) in-
kind, in the form of AD syringes and safety boxes, and 2) in cash, for those countries that already had a secure, multi-year
source of AD syringes and safety boxes, but proposed to use INS support to strengthen their injection safety activities. In
total, GAVI gave INS support for a three-year period to 58 countries: 46 with commodities and 12 with cash support. To
identify variables that might be associated with financial sustainability, frequencies and cross-tabulations were run against
various programmatic and socio-economic variables in the 58 countries. All but two of the 46 commodity-recipient
countries were able to replace and sustain the use of AD syringes and safety boxes after the end of their GAVI INS support
despite the fact that standard disposable syringes are less costly than ADs (10–15 percent differential). In addition, all 12
cash-recipient countries continued to use AD syringes and safety boxes in their immunization programs in the years
following GAVI INS assistance. At the same time, countries were often not prepared for the increased waste management
requirements associated with the use of the syringes, suggesting the importance of anticipating challenges with the
introduction of new technologies. The sustained use of AD syringes in countries receiving injection safety support from
GAVI, in a majority of cases through government financing, following the completion of three years of time-limited support,
represents an early indication of how GHPs can contribute to improved health outcomes in immunization safety in the
world’s poorest countries in a sustainable way.
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Introduction
Global health partnerships (GHPs) have assumed an increas-
ingly important role in financing global health [1,2] and
influencing related policies and activities at the country and global
levels [3]. Yet the base of empirical evidence on the sustainability
of GHP support remains limited. In at least 16 countries, GHP
commitment is so large that it exceeds 5% of a government’s
expenditure [1], leading to concerns that low-income countries
may not be able to match the ongoing costs once the funding ends,
and that the support may pose major challenges in terms of
macroeconomic management.
This paper uses evidence from the GAVI Alliance’s (formerly
Global Alliance for Vaccines and Immunization) Injection Safety
Support program to assess the effectiveness and sustainability of
time limited support in changing country practices known to lead
to improved immunization safety. The GAVI Alliance, formed in
1999, serves to promote and finance new and under-utilized
vaccines, as well as to improve immunization services. It is
considered a global health partnership since it maintains a
collaborative relationship among multiple organizations that share
risks and benefits in pursuit of a shared goal [4].
Starting in 2002, GAVI offered Injection Safety Support to
countries with per capita income of less than $1000 as one of its
funding windows. The recent evaluation of this program is a prime
opportunity for understanding the sustainability issues associated
with time-limited GHP funding to low-income countries.
The GAVI Injection Safety Support window was meant to be
catalytic and time-limited. In line with GAVI funding policies,
countries with a Gross National Income (GNI) per capita below
US$1,000 in 2003 qualified for this support. Countries approved
for support would receive stocks of injection safety supplies to
cover National Immunization Program (NIP) injections for
children and women. For countries that already had funding for
injection safety supplies, they could instead apply for cash support
for program-strengthening activities related to injection safety.
The objective of the program was to catalyze recipient countries to
introduce auto-disable (AD) syringes and continue to use these
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from GAVI, with government financing or joint government and
donor financing. For countries already using injection safety
supplies (twelve countries), the objective was to support their
continued use.
The supplies funded in the Injection Safety Support window are
AD syringes and safety boxes for disposal of the used syringes. AD
were developed by WHO in 1986 to counter the health threats
posed by a) inappropriate handling and use of syringes designed to
be reusable through proper sterilization and b) inappropriate reuse
of standard, disposable syringes. The AD syringe is a single-use
device and has a mechanism that disables the plunger after its first
use. This support, which began in 2002, was complementary to
GAVI’s provision of new and underused vaccines. Since all new
and underused vaccines offered by GAVI were provided jointly
with injection safety supplies, Injection Safety Support only
provides AD syringes and safety boxes for other NIP program
vaccines (e.g. BCG, measles, DTP). By the end of 2006, 58
countries had completed their three years of injection safety
support at a total cost of $110 million.
The adoption of AD syringes is cost-effective [5] from a societal
perspective – i.e. the additional cost of using AD syringes is
relatively small while the benefits of avoiding needle re-use are
very pronounced. GAVI’s injection safety support could poten-
tially catalyze safe injection practices, and reduce blood-borne
diseases such as Hepatitis B and C and Human Immunodeficiency
Virus (HIV). At the time when GAVI was started, unsafe injections
were estimated to be accountable for 1.3 million early deaths each
year, and up to 40% of all injections in the world were given with
reused syringes without sterilization [6].
This study investigates whether countries will continue using a
new injection technology after a time-limited support of a GHP
ends despite the fact that the standard injection supplies are less
costly (10–15 percent differential). The factors that affected a
country’s likelihood of continuing the use of the new technology
are identified. In addition, the program’s impact on the use of
infection safety supplies in the broader health sector was also
examined.
Methods
The study sample includes the 58 countries (see Table 1 for list
of countries and Table 2 for selected characteristics) that
completed their three years of Injection Safety Support by the
end of 2006. The key outcome of interest is whether all 58
countries were able to sustain the use of AD syringes and safety
boxes after GAVI support had ended. For this study, sustainability
is considered to include two aspects, namely, replacement and
financial sustainability. Replacement of GAVI support is considered
the minimum requirement for injection safety practices to be
sustained. Replacement is considered to have occurred when a
country continues the use of AD syringes and safety boxes after
GAVI INS support has ended, irrespective of the source(s) of
financing. Financial sustainability takes into account the concept of
self–sufficiency and is defined as the extent to which GAVI INS
support is sustained through the resources of the country itself
rather than external partners. The four levels of financial
sustainability were the following: (1) None: AD syringes not
replaced or partially replaced; (2) Low: replaced but fully donor
dependent; (3) Medium: replaced with mixed government and
donor funding; and (4) High: replaced with full domestic funding.
The data collection involved three methods: 1) Review of
available documentation on injection safety and waste manage-
ment in the 58 countries including country applications for
funding, annual progress reports, government and partner
meetings, and WHO/UNICEF statistics on country immunization
coverage, injection safety, program financing, and healthcare
waste management; 2) telephone interviews with NIP or Ministry
of Health program managers; and 3) telephone interviews with
WHO and UNICEF regional and country focal points. To verify
the findings, country reports on the use of injection safety supplies
after GAVI funding ended were checked against data from
UNICEF Supply Division on the procurement of AD syringes and
safety boxes. By mid-2008 when the data was collected, each
country had been without GAVI support for at least two years.
In the analysis, the study team evaluated the importance of
factors that affect the extent to which AD syringes and safety boxes
were funded with government funding, using the financial
sustainability framework in Figure 1. The variables created for
the analysis of the sustainability of injection safety support are
shown in Table 3.
To identify variables that might be associated with financial
sustainability, frequencies and cross-tabulations are run against
various programmatic and socio-economic variables in the 58
countries. The analysis is stratified by whether the country had
introduced a new injection technology, i.e. received commodities,
or received funding to supplement its already existing injection
safety activities, i.e. received cash.
A key limitation of the study lay in its retrospective nature and
its reliance on NIP managers. In some countries, NIP staff
turnover meant that the managers were not at their posts when the
application was written, or when the decision was made to replace
GAVI’s Injection Safety Support. Also, some NIP managers were
Table 1. List of Countries Receiving GAVI Injection Safety
Support.
2002–2004 2003–2005 2004–2006
Armenia Azerbaijan Afghanistan (cash)
Burundi Bhutan Albania
Cambodia Burkina Faso Angola
Djibouti (cash) Cameroon Bangladesh
Ethiopia CAR Bolivia
Gambia Comoros Chad
Georgia Congo DR China (cash)
Korea DR Ghana (cash) Congo
Lao PDR Indonesia Eritrea
Senegal Kenya Guinea
Sierra Leone Lesotho Haiti (cash)
Sudan Mali Honduras (cash)
Uganda Mozambique Kyrgyz Rep.
Yemen (cash) Myanmar Mauritania (cash)
Zambia Nepal Niger
Pakistan Sri Lanka
Rwanda (cash) Tajikistan
Sao Tome Turkmenistan
Somalia (cash) Ukraine
Tanzania (cash) Vietnam (cash)
Togo Zimbabwe
Uzbekistan
doi:10.1371/journal.pone.0012986.t001
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broader health sector. A further limitation was the fact that
GAVI’s injection safety support had only ended in 2006 in 21 out
of 58 countries.
Results
Financial sustainability among the 46 Commodity-
recipient Countries
In terms of sustainability, all but two of the 46 commodity-
recipient countries (ninety-six percent) continued to use AD
syringes and safety boxes after GAVI support ended. By mid-2008,
more than half (25 countries, fifty-four percent) of these countries
were financing the purchase of their own AD syringes and safety
boxes completely with government funding and seven (15 percent)
were using a mixture of government and donor funding. Only 12
(26 percent) countries continued to be totally donor dependent (see
Table 4 for a summary).
Two of the 58 countries in the study at least partially
discontinued the use of AD syringes for different reasons. Ukraine
discontinued its use of AD syringes and safety boxes and opted
instead to use its local production of standard disposable syringes.
The second country, Uzbekistan, discontinued the use of AD
syringes and safety boxes in three-quarters of its health facilities
Table 2. Characteristics of the 46 commodity-recipient countries and 12 cash-recipient countries.
Number (%)
Characteristics Categories Recipients of supplies Recipients of cash
Year support ended 2004 13 (28%) 2(17%)
2005 18(39%) 4(33%)
2006 15(33%) 6(50%)
Regions (based on WHO
categorization)
Africa 25 (54%) 4 (33%)
Latin America 1(2%) 2 (17%)
Eastern Mediterranean 2 (4%) 0(0%)
Europe 9(20%) 4(33%)
South-east Asia 7(15%) 0(0%)
West Pacific 2(4%) 2(17%)
GNI per capita ,=$350 13(28%) 2(17%)
$350–700 14(30%) 3(25%)
.$700 17(37%) 5(42%)
No data 2(4%) 2(17%)
doi:10.1371/journal.pone.0012986.t002
Figure 1. Financial Sustainability Framework. This figure describes the levels of the health system that affect financial sustainability of funding
for injection safety. The abbreviations in the article are the following: NIP = National Immunization Program, GDP = Gross Domestic Production, and
GHP = Global Health Partnership.
doi:10.1371/journal.pone.0012986.g001
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governments in Uzbekistan have decentralized procurement and
are responsible for expenditure related to primary care units [7],
some authorities at the oblast level chose non-AD products rather
than AD products.
Determinants of financial sustainability among the 46
Commodity-recipient Countries (Bivariate results)
When grouped by WHO region, the percentage of countries
that funded their AD syringes and safety boxes from a government
source ranged from 43 percent in the South-east Asia (three
countries) to 100 percent in Latin America (three countries) and
Eastern Mediterranean (two countries) (see Figure 2).
Some sixty percent of African countries had government
funding for their AD syringes and safety boxes. However, this
percentage was higher in West Africa (90%) than in other parts of
Africa (see Figure 3). The explanation for this difference may be
attributed to effective advocacy by WHO and UNICEF technical
focal persons and donor budget support for the national
immunization programs including vaccines and essential supplies.
In addition, the European Union (EU) requested donor-assisted
countries in West Africa to establish MOH budget line items for
vaccines and injection safety commodities when they received
support. Part of the Vaccine Independence Initiative (VII), the EU
helped countries to purchase vaccines and injection safety
commodities by guaranteeing the payment.
Seventy one percent of countries with a per capita income over
USD 700 were fully government funded for AD syringes and
safety boxes after the conclusion of GAVI’s support, compared to
54% or less for the countries in the poorer income groups, but this
factor was not statistically significant (see Table 5).
Countries with stronger programs were slightly more likely to be
able to replace GAVI funding with government funding, or with a
mixture of government and donor funding than were countries
with medium or weak program strength (Table 6). (See
explanation of the program strength variable in Table 3.) It is,
however, clear that this factor alone does not account for financial
sustainability because three countries with weak programs have
Table 3. Variables on Sustainability of Injection Safety Support.
OUTCOME VARIABLE
Score/Range Level of sustainability of injection safety Support in Immunization Program
1 Discontinued use of AD syringes and safety boxes
2 Dependent on donors to finance
3 Government is financing a proportion of the expenditures
4 Government is financing all AD syringes and safety boxes
DEPENDENT VARIABLES
GNI per capita
1–3 Score based on whether country has a per capita income #$350, $351–700, or .$700
Region
1–6 Six regions are Western Pacific, Southeast Asia, Africa, Latin America, Europe and Eastern Mediterranean
Program strength
1–5 Score based on whether DTP3 coverage $80 percent, country has a national injection safety policy, NIP manager rated the immunization program
logistics as mostly or completely adequate, injection safety has a strong advocate in the MOH or partner organization and program maintains a
continuous supply of AD syringes and safety boxes
Year that support ended
1–3 The years that support ended range from 2004 to 2006.
Decision-making
1–3 Score based on whether the adequacy of decision-making process on replacement was rated as none or little, some or excellent
doi:10.1371/journal.pone.0012986.t003
Table 4. Financial sustainability among commodity and cash recipients.
Level of financial sustainability Number (%) of Countries
Recipients of supplies Recipients of cash
None: Total/partial discontinuation of AD syringes 2 (4%) 0 (0%)
Low: Fully donor-dependent for financing 12 (26%) 4 (33%)
Medium: Mixture of government and donor funding 7 (15%) 3 (25%)
High: Fully government funded 25 (54%) 5 (42%)
Total 46 (100%) 12 (100%)
doi:10.1371/journal.pone.0012986.t004
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countries with high program strength have total or partial
discontinuation of AD syringes.
Countries that ended their support in 2004 were more likely (62
percent) by the time of the evaluation to have secured government
funding for their AD syringes and safety boxes than countries
ending in 2005 (56 percent) or 2006 (47 percent) (Table 7).
Countries with a better decision-making process, based on whether
program managers rated the adequacy of the process on
replacement as excellent, some, little or none, also were more
likely to have government funding for AD syringes and safety
boxes. (Table 8).
Financial Sustainability of Countries receiving Cash
instead of Injection Safety Materials
All 12 cash recipient countries continued to use AD syringes and
safety boxes in their NIP after the end of GAVI support. Among
them, five purchased AD syringes and safety boxes with full
government funding. Among the other seven countries, three
purchased supplies using a combination of government and donor
support, while the remaining four countries continued to use only
donor funding (refer to Table 4 for a summary).
Cash-recipient countries mainly used GAVI funding to support
injection safety in their programs. Four of the 12 countries
(Afghanistan, Djibouti, Haiti and Honduras) used the support to
reinforce the use of AD syringes and safety boxes through program
areas such as training, monitoring, supervision and evaluation.
Three countries (Ghana, Mauritania and Tanzania) used the
funding to construct incinerators for disposal of used syringes. Two
countries (China and Vietnam) used GAVI INS support to
purchase AD syringes and safety boxes from local manufacturers
per their agreements with GAVI. In the three countries (Rwanda,
Somalia and Yemen) that used the funding to purchase AD
syringes and safety boxes internationally, GAVI made agreements
to transfer cash to these countries because of their particular
circumstances. In Somalia, for example, an agreement was made
with UNICEF to purchase the syringes so that it could continue to
provide commodities to a country which is considered ‘‘fragile.’’
Another country – Yemen, was already using its World Bank loan
to purchase AD syringes, and used GAVI INS cash support to
replace this source of funding.
Impact on broader health sector
The majority of program managers interviewed stated that
GAVI’s injection safety support was influential on the decision to
introduce AD syringes and safety boxes into other health services.
Thirty countries, (51% of total countries), introduced AD syringes
and safety boxes partially (20 countries) or fully (10 countries) into
other non-immunization services. In 21 of the countries, AD
syringes were introduced into other services during or after the
GAVI support took place while 9 countries already were using
these products.
Program managers also stated that GAVI’s support influenced
the development of injection safety policies for the health sector.
Of the 39 countries that had a policy or were developing one, 35
program managers stated that GAVI’s support influenced the
development of this policy by increasing their awareness of
injection safety issues.
The introduction of AD syringes also resulted in additional
waste disposal requirements in many of the countries. Program
managers in a third of the countries (19) stated that health care
waste management is an unresolved problem for their health
Figure 2. Financial sustainability by region. This figure shows the extent to which countries in different regions are using government funding
to purchase AD syringes after GAVI funding ended. The green section of each bar represents the percent of countries that are fully government
funded, the yellow section represents the countries that use a mixture of government and donor financing, the orange section is for countries that
only use donor financing, and the clear section is for countries that have totally or partially discontinued the use of AD syringes.
doi:10.1371/journal.pone.0012986.g002
Figure 3. Financial sustainability in Africa. This figure shows the
extent to which countries in Africa are using government funding to
purchase AD syringes after GAVI funding ended. The green section of
each bar represents the percent of countries that are fully government
funded, the yellow section represents the countries that use a mixture
of government and donor financing, and the orange section of the light
is for countries that only use donor financing.
doi:10.1371/journal.pone.0012986.g003
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had a policy on health care waste management, about one-third
(19) of program managers considered it an unresolved problem.
Sixteen reported a lack of incinerators, one cited difficulties
maintaining incinerators, and two mentioned unsafe disposal of
waste.
Comparison of use of AD syringes in GAVI INS recipients
with non-GAVI lower-middle income countries
The use of AD syringes is higher in GAVI INS-supported
countries than in non-GAVI lower middle-income countries
(Table 9). However, it is not only the lack of eligibility for GAVI
support that is affecting these countries. Discussions with regional
WHO/UNICEF focal points indicate that some middle-income
countries in the EUR and AMR regions do not perceive that AD
syringes are necessary for their countries because they do not
believe that their health facilities re-use single-use syringes.
However data from this evaluation indicated that health ministry
officials wanted to continue using AD syringes once they had been
introduced into their country’s immunization programs.
Discussion
GAVI’s injection safety support was instrumental in accelerating
the introduction of AD syringes and safety boxes in low-income
countries. Although the support was limited to three years, this
evaluation study showed that almost all countries receiving the
support (96%) continued to procure and utilize AD syringes and
safety boxes in the years after GAVI support came to an end. The
countries continued use of the AD syringes despite the fact that
they were more costly than standard disposable syringes (10–15
percent differential). Furthermore, a majority of the countries
receiving support continued the use of these devices using only
government funding. In addition, the use of AD syringes is higher
in GAVI INS-supported countries than in non-GAVI lower
middle-income countries. These findings demonstrate some
evidence of the potential impact that GHPs can achieve through
targeted time-limited support to countries.
One of the reasons for GAVI’s success was that AD syringes
were only slightly more costly than standard disposable syringes at
the time of evaluation. From 1992 to 2001, the average price of an
AD syringe decreased from U.S. $0.13 to U.S. $0.06 (UNICEF
Supply Division). GAVI launched its support after this substantial
drop in price, and thus did not drive any further significant
reductions in price. By the time GAVI countries were expected to
assume the cost of procuring AD syringes, the price was sufficiently
low to make it easier and more affordable for governments to
begin procuring on their own. It is possible that if the price
differential between the new and older technologies had been
higher, that countries would be less likely to continue with the new
technology.
Another factor in sustaining the use of injection safety supplies
was the advocacy efforts of global and regional partners. These
included WHO, UNICEF and the European Union. In the
African region, for example, the regional WHO Task Force on
Immunization (TFI) issued a statement in 2002 recommending the
use of AD syringes for national immunization programs. The
statement was used successfully to achieve a transition to this
technology in most countries in this part of the region. Another
partner, the European Union (EU), requested donor-assisted
countries in West Africa to establish MOH budget line items for
vaccines and injection safety commodities when they received
support. This led to a higher level of sustainability observed in
West Africa as compared to other parts of the continent.
The additional waste management requirements imposed by
AD syringes were perceived by NIP managers interviewed and
some regional WHO or UNICEF focal persons as a growing
problem that needed addressing. Even though some countries
received technical assistance and donor support to construct
incinerators through non-GAVI initiatives (such as through
Table 5. Financial sustainability of Countries by Per Capita Income Level.
GNI per capita (U.S.$) #$350 (%) $351–$700 (%) .$700 (%) Total
None: Total/Partial discontinuation of AD syringes 0 (0) 1 (7) 1 (6) 2 (5)
Low: Fully Donor-dependent for Financing 5 (38) 3 (24) 2 (12) 10 (23)
Medium: Mixture of Government and Donor funding 1 (8) 4 (29) 2 (12) 7(18)
High: Fully Government Funded 7 (54) 6 (43) 12 (71) 25(54)
Total 13 14 17 44
Pearson Chi Square =7.774 (p,0.456).
doi:10.1371/journal.pone.0012986.t005
Table 6. Financial sustainability of Countries by program strength.
Level of Sustainability
Weak (program
strength 1–2) (%)
Medium (program
strength 3) (%)
High (program
strength 4–5) (%)
Total
Number (%)
None: Total or partial discontinuation of AD syringes 0 (0) 0 (0) 2 (9) 2 (5)
Low: Fully Donor-dependent for Financing 2 (40) 5 (45) 2 (9) 9 (23)
Medium: Mixture of Government and Donor funding 0 (0) 1 (10) 6(26) 7 (18)
High: Fully Government Funded 3 (60) 5 (45) 13 (57) 21 (54)
Total 5 11 23 39
Pearson chi-square =15.747 (p,0.471).
doi:10.1371/journal.pone.0012986.t006
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durability that was necessary for prolonged use. Coordinated,
scaled-up efforts from donors and global health partnerships are
therefore necessary for the implementation of health care waste
management plans developed in the countries.
Our study showed that the exclusive use of AD syringes in
immunization programmes in low-income countries could poten-
tially be sustained in the long-term, which was contrary from what
some critics wrote [8,9] on the sustainability of this approach of
achieving injection safety.
WHO estimates that only 3% of all injections are administered
for immunization—95% of all injections occur in delivery of
curative services [10]. The successful achievement of injection
safety thus also lies in low-income countries’ ability to reduce the
number of inappropriate injections given. The dissemination of
information, education and communication (IEC) materials and
behaviour change campaigns targeting patients and health
workers were thus identified by the Safe Injection Global Network
(SIGN) as a key strategy in achieving injection safety.
Some spillover effects of introducing AD syringes in NIP
towards the curative sectors were identified. However, a more
comprehensive study will need to be done to tease out the
intervention’s impact and investigate whether other confounding
effects on the timing of the introduction were taking place as well.
GAVI was successful in taking an innovative approach to
enhancing injection safety among NIP in low-income countries.
Through providing a catalytic, time-limited support in cash or
supplies, countries were either able to replace unsafe injection
safety supplies with AD syringes and safety boxes, or to enhance
their existing injection safety initiatives through training, moni-
toring, local procurement or waste management of injection
wastes. It suggests that low resource countries, which are recipients
of time-limited in-kind or monetary support, can be induced or
catalyzed to change their health practices.
Conclusion
The sustained use of AD syringes in countries receiving
injection safety support from GAVI, in a majority of cases
through government financing, following the completion of three
years of time-limited support represents an early indication of
how GHPs can contribute to improved immunization safety in
the world’s poorest countries in a sustainable way. The support
also had further-reaching effects in catalyzing the use of injection
safety supplies in other services beyond NIP, and in influencing
the development of a health-sector wide policy on injection
safety.
The sustainability of GHP efforts hinges upon the ability of
various actors to work in effective partnerships. The participation
of implementing governments, donors and multilateral agencies is
important, as shown in the decision-making and planning process
of replacing GAVI’s supply. It is critical that a plan be made for
replacing donor funding in advance of the end of the time-limited
support window. Regional variations show that the advocacy
efforts of international agencies such as WHO and UNICEF are
important in encouraging governments of these countries to take
up the funding of injection safety themselves.
Although this study alone cannot provide a comprehensive
conclusion on the sustainability of time-limited programs, it
contributes important evidence on an issue of increasing
importance. GHPs should design support mechanisms to increase
the likelihood that governments will be able to sustain desired
outcomes following completion of the time-limited support.
Additional research studies are needed to better understand
program characteristics that are associated with increased
sustainability of GHP support. Rigorous monitoring and evalua-
tion of programs is also needed, and should include ongoing
monitoring following the completion of time-limited support to
assess the degree to which desired outcomes are sustained over
time.
Table 7. Financial sustainability of Countries by year in which GAVI Injection Safety Support ended.
Level of financial sustainability 2004 2005 2006 Total (%)
None: Total or partial discontinuation of AD syringes 0 (0%) 1 (6%) 1 (7%) 2 (4%)
Low: Fully donor dependent for financing 4 (31%) 5 (28%) 3 (20%) 12 (26%)
Medium: Mixture of government and donor funding 1 (8%) 2 (11%) 4 (27%) 7 (15%)
High: Fully government funded 8 (62%) 10 (56%) 7 (47%) 25 (54%)
Total 13 18 15 46
Pearson chi-squared =5.829 (p,0.666).
doi:10.1371/journal.pone.0012986.t007
Table 8. Financial Sustainability of Countries by Adequacy of Decision-making.
Little or No Process Some Excellent
None: Total or partial discontinuation of AD syringes 1 (25) 1 (10) 0 (0) 2
Low: Fully Donor-dependent for Financing 1 (25) 0 (0) 7 (28) 8
Medium: Mixture of Government and Donor funding 2 (50) 2 (20%) 3 (12) 7
High: Fully Government Funded 0 (0) 7 (70%) 15 (45) 22
Total 41 0 2 5 3 9
Pearson Chi-square =36.752 (p,0.013).
doi:10.1371/journal.pone.0012986.t008
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Table 9. Type of syringes used in GAVI INS countries and non-GAVI lower-middle income countries.
Type of syringes used in immunization program GAVI INS recipients
Non-GAVI lower-middle
income countries
Fully using AD syringes 56 (96) 11 (41)
Using mixture of AD and non-AD syringes 1 (2) 10 (37)
Fully using non-AD syringes 1 (2) 6 (22)
Source: JRF 2007 and telephone interviews with program managers and WHO and UNICEF staff.
doi:10.1371/journal.pone.0012986.t009
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